<DOC>
	<DOCNO>NCT00971035</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , four-arm , dose-ranging study . The purpose evaluate relationship dose lebrikizumab response term efficacy , safety , tolerability patient asthma inhaled steroid .</brief_summary>
	<brief_title>A Study Evaluate Lebrikizumab ( MILR1444A ) Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Body weight ≥ 50 kg ≤ 150 kg Visit 1 Chest radiograph within 12 month Visit 1 without evidence clinically significant abnormality Stable asthma Asthma exacerbation screen Known malignancy Known immunodeficiency Preexisting lung disease asthma Uncontrolled clinically significant medical disease Current smoker History substance abuse may impair risk patient 's full participation study , judgment investigator Prior allergic reaction monoclonal antibody Patients ( men woman ) reproductive potential willing use contraception Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MILR1444A</keyword>
</DOC>